Please assess the completion status of the following clinical trial:

Trial Title: Study of CS-3150 in Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged 20 years or older at informed consent~* Subjects with essential hypertension satisfying the following blood pressure criteria;~  * Sitting SBP: ≥ 140 mmHg and \< 180 mmHg~ * Sitting DBP: ≥ 90 mmHg and \< 110 mmHg~ * Mean 24 hr BP: SBP ≥ 130 and DBP ≥ 80 mmHg~Exclusion Criteria:~* Secondary hypertension or malignant hypertension~* Diabetic nephropathy or diabetes mellitus with albuminuria~* Serum potassium level \< 3.5 or ≥ 5.1 mEq/L~* Reversed day-night life cycle including overnight workers~* eGFR \< 60 mL/min/1.73 m\^2

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CS-3150 2.5 mg (Type: EXPERIMENTAL): CS-3150 2.5 mg, orally, once daily after breakfast for 12 weeks
- CS-3150 5.0 mg (Type: EXPERIMENTAL): CS-3150 5 mg, orally, once daily after breakfast for 12 weeks
- Eplerenone (Type: ACTIVE_COMPARATOR): Eplerenone 50 mg, orally, once daily after breakfast for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).